A new clinical trial is underway to evaluate the efficacy of Elafibranor in patients with Primary Biliary Cholangitis who have not responded adequately to Ursodeoxycholic Acid.

ClinicalJuly 9, 2026

4D Flow MRI Study Aims to Improve Risk Stratification for Variceal Bleeding in Cirrhosis

A study is underway to validate non-invasive MRI biomarkers for detecting gastroesophageal varices in cirrhosis patients.

ClinicalJuly 8, 2026

Study Compares Large Volume Paracentesis and TIPS for Ascites Relief

A clinical trial is underway comparing Large Volume Paracentesis with albumin infusion to early TIPS for treating ascites.

ClinicalJuly 5, 2026

Long-term Study on Odevixibat Effectiveness for PFIC in South Korea Initiated

A new study has been initiated in South Korea to evaluate the long-term effectiveness and safety of odevixibat in patients with PFIC.

RegulatoryJuly 4, 2026

Semaglutide (Wegovy) approved for metabolic-associated steatohepatitis treatment

Semaglutide injection has received approval for the treatment of metabolic-associated steatohepatitis in adults with moderate-to-advanced liver fibrosis.

ClinicalJuly 3, 2026

Ipsen initiates trial for elafibranor in Primary Sclerosing Cholangitis

Ipsen is conducting a trial to assess the efficacy and safety of elafibranor in adult patients with Primary Sclerosing Cholangitis.

ClinicalJuly 2, 2026

Exosome-based delivery of Wedelolactone shows promise for sepsis-induced liver injury

A novel exosome-based drug delivery system (Exo@WEL) enhances liver-targeting and hepatoprotection of Wedelolactone.

ClinicalJune 29, 2026

Akero Therapeutics Initiates Study of Efruxifermin in NASH/MASH Patients

Akero Therapeutics is conducting a multi-center, randomized, double-blind, placebo-controlled study of efruxifermin in patients with non-cirrhotic NASH/MASH and fibrosis.

ClinicalJune 27, 2026

Vir Biotechnology Initiates Phase 2 Trial for Chronic Hepatitis D with VIR-2218 and VIR-3434

Vir Biotechnology is conducting Phase 2 trial assessing the safety and efficacy of combination therapy with VIR-2218 and VIR-3434 for chronic hepatitis D infection.

ClinicalJune 25, 2026

Boehringer Ingelheim's Survodutide Trial for NASH/MASH with Cirrhosis Underway

Boehringer Ingelheim is conducting a trial to evaluate the efficacy of survodutide in adults with NASH or MASH and cirrhosis.

ClinicalJune 22, 2026

Tirzepatide Trial for Metabolic Alcohol-Associated Liver Disease in AUD Patients

A clinical trial is underway to evaluate the efficacy of Tirzepatide in patients with Alcohol Use Disorder and MetALD.

RegulatoryJune 21, 2026

FDA Accepts Supplemental NDA for Terlivaz by Mallinckrodt

The FDA has accepted a supplemental NDA for Terlivaz (terlipressin acetate) submitted by Mallinckrodt.

ClinicalJune 20, 2026

Novel Oral Nanoemulsion Targets Hepatic Stellate Cells in Liver Fibrosis Treatment

A vitamin A-functionalized self-nanoemulsifying drug delivery system effectively targets hepatic stellate cells in liver fibrosis.

CompetitiveJune 16, 2026

Roche Launches Liver Disease Panel to Enhance Chronic Liver Disease Management

Roche has launched the Liver Disease Panel, a suite of certified algorithms aimed at improving the management of chronic liver disease (CLD). This panel includes the LiverPRO algorithm, which facilitates early detection of liver fibrosis using routine blood markers.

ClinicalJune 11, 2026